|
August 11th, 2005
Taylor Madison Corp. (Pink Sheets:TMDN) and its wholly-owned
subsidiary Telzuit Technologies, Inc. have entered into a 12 month agreement with AlphaMedica, a medical education and communications
company, to provide marketing services for its BioPatch Platform. AlphaMedica, as part of the agreement, will market the
BioPatch Wireless Holter Monitor, a 12 lead biopatch wireless heart monitor. The device is expected to be available on the
market sometime in 2005. AlphaMedica is also expected to market Taylor Madison’s other products scheduled for 2006.
Among these is a BioPatch Wireless Cardiac Event Monitor.
Commenting on the selection of AlphaMedica was Donald
Sproat, CEO of Taylor Madison and Telzuit, "AlphaMedica is a quality company that has proven experience in both the cardiovascular
and medical device fields. We are leveraging the same people in their company that work with some of the foremost companies
in the world such as Pfizer, Allergan, Aventis and Forrest Laboratories Inc. I have witnessed their effectiveness firsthand
and believe that their diligence, dedication and creativeness applied in the same manner with BioPatch products will produce
the exposure and use Telzuit is looking for."
The Bio-Patch, according to Telzuit Medical Technologies
is an FDA approved EKG heart-monitoring device intended for the $81billion dollar outpatient heart disease treatment
market. Telzuit completed a private placement for $4.2 million on June 29th, 2005.
|
